Global Molecular Infectious Disease Testing Market OverviewThe global molecular infectious disease testing market is ...

During the COVID-19 pandemic, a staggering 340 million tests for the virus were supplied across the world by a company based in South Korea that specializes in so-called syndromic real-time polymerase ...

cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, ...

NEW YORK – Lex Diagnostics said on Monday that it has obtained 510 (k) clearance and CLIA waiver from the US Food and Drug Administration for its Velo point-of-care molecular diagnostic system and an ...

Many people will have experienced being unwell with an unknown infection and having to undergo multiple tests to determine the culprit. This sequential process of elimination can be time-consuming and ...

Polymerase chain reaction (PCR) tests are one of the most popular diagnostic tools for the detection and diagnosis of viral diseases, such as coronavirus (COVID-19), due to their ability to rapidly ...

The new system will advance personalised healthcare and support outbreak readiness by delivering agility and flexibility for translational research and diagnostics. The innovative features of the ...

The LightCycler PRO System is designed to be the most advanced qPCR technology for both clinical diagnostics and research. The new system will advance personalised healthcare and support outbreak ...

The system is intended for use in urgent care clinics, primary care settings, physician office laboratories, and pharmacies.

The Canada Point of Care Molecular Diagnostics Market, valued at USD 350 million in 2024, is projected to reach USD 560 ...

Patients in rural communities often lack timely access to innovative infectious disease testing because diagnostic laboratories are located far away. Long transport times and logistical barriers delay ...

Infectious Disease Diagnostics Market Size To Reach USD 63.26 Billion By 2035, Driven By Rapid Testing Adoption And Molecular Diagnostics Advancements SNS Insider. Global Infectious Disease ...